|
Home:
CME Audio Series and Activity
Prostate Cancer Update: A CME Audio Series and Activity
Statement of need /Target audience
Prostate cancer is one of the most rapidly evolving fields in
urology. Published results from clinical trials lead to the emergence
of new surgical and radiation therapy techniques as well as therapeutic
agents, along with changes in the indications for existing treatments.
In order to offer optimal patient care — including the option
of clinical trial participation — the practicing urologist
must be well-informed of these advances.
To bridge the gap between research and patient care, Prostate
Cancer Update utilizes one-on-one discussions with leading urologic
oncology investigators. By providing access to the latest research
developments and expert perspectives, this CME program assists physicians
in the formulation of up-to-date clinical management strategies.
Issue 1, 2002 of Prostate Cancer Update consists of discussions
with five research leaders on a variety of important issues, including
nerve-sparing radical prostatectomy, brachytherapy, the use of bisphosphonates
to prevent skeletal events, early versus delayed hormonal therapy,
adjuvant bicalutamide and second- and third-line hormonal therapies.
Educational objectives
Upon completion of this activity, participants should be able
to:
- Discuss the risks and benefits of nerve-sparing radical prostatectomy.
- Review the risks and benefits of early versus delayed hormonal
therapy in men with prostate cancer.
- Summarize the study design and results from the Early Prostate
Cancer (EPC) trials, which evaluated bicalutamide as immediate
or adjuvant therapy in men with prostate cancer.
- Examine the emerging role of bisphosphonates in men with prostate
cancer.
- Evaluate the long-term outcomes associated with brachytherapy.
- Discuss potential second- and third-line hormonal therapies
for men with prostate cancer.
Accreditation statement
This activity has been planned and implemented in accordance with
the Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint sponsorship
of the Postgraduate Institute for Medicine and NL Communications,
Inc.
The Postgraduate Institute for Medicine is accredited by the ACCME
to provide continuing medical education for physicians and takes
responsibility for the content, quality and scientific integrity
of this CME activity.
Designation statement
The Postgraduate Institute for Medicine designates this educational
activity for a maximum of 3 hours in category 1 credit toward the
A M A Physician's Recognition Award. Each physician should claim
only those hours of credit that he/she actually spent in the activity.
Faculty disclosure statements
The Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or apparent
commercial financial affiliations related to the content of their
presentations/materials. It is not assumed that these financial
interests or affiliations will have an adverse impact on faculty
presentations; they are simply noted in this supplement to fully
inform participants.
|
